The heart of the matter is clear: Huntsville’s recent victory in landing Eli Lilly’s massive new pharmaceutical manufacturing plant should be a wake-up call for Birmingham—and perhaps even a source of genuine concern. But here’s where it gets controversial: while many have always considered Birmingham the dominant force in Alabama’s life sciences sector, the recent developments in Huntsville suggest that the balance of power may already be shifting, and that means Birmingham needs to pay close attention.
Let’s delve into the details and understand why Huntsville’s success could be a game-changer—and what Birmingham might be missing.
In 2020, I authored a novel titled Buffalo Hunting in Alabama, which explored economic development among other themes. One of its storylines involved Alabama competing against other states to secure a major pharmaceutical plant—specifically, a large-scale project. In the story, the Birmingham metropolitan area was the winning candidate. But as real life imitates fiction, the actual outcome turned out differently. While I correctly identified Alabama as a key player, the city that actually secured the project wasn’t Birmingham—it was Huntsville.
Congratulations are in order for Huntsville, which has just been announced as the site for Eli Lilly’s new $6 billion, 450-job pharmaceutical facility—an investment showcasing the city’s growing clout in the industry. This facility will also create around 3,000 construction jobs, and the entire initiative underscores Huntsville’s rising prominence in high-tech manufacturing—and Alabama’s strategic importance in the national and global pharmaceutical landscape.
Despite having a smaller population—less than half of Birmingham’s—the Huntsville metro has demonstrated an extraordinary ability to attract major projects, ranging from military commands like Space Command to tech giants such as Meta, automotive companies like Toyota and Mazda, and now pharmaceutical giants like Eli Lilly. With such accomplishments, it’s clear that Huntsville’s influence is expanding rapidly.
Both Birmingham and Huntsville host some mid-sized biotech operations, but according to recent reports, Eli Lilly explicitly credited its choice of Huntsville in part because of the proximity to the HudsonAlpha Institute for Biotechnology. This world-class research institution offers a significant advantage for biotech and pharmaceutical development, truly anchoring Huntsville’s reputation as a biotech hub.
To understand the evolving landscape, consider a 2024 study by the Waymaker Group, which aimed to guide Birmingham’s suburb Hoover in identifying promising industries to attract. Many believed the report would recommend pursuing more life sciences companies, given Birmingham's presence with UAB and Southern Research, as well as Hoover's local biotech firms like Biocryst and Biohorizons. Instead, the report was surprisingly candid:
“UAB is a top-tier research institution, directing over $713 million annually toward life sciences R&D. Yet, their outcomes in turning research into commercial products—what’s called tech transfer—are dismal compared to other leading universities.
